Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > When is phase III trial going to start?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 05, 2021 11:11am
295 Views
Post# 33335916

RE:RE:When is phase III trial going to start?

RE:RE:When is phase III trial going to start?
Bookworm28 wrote: ...sorry, the Co also said last year.... " while at the same time expeditiously moving forward with phase III development. This parallel strategy is important, as partnering outreach and execution are an extensive, involved process, and the continued advancement of the drug's development program is expected to increase market value and negotiating leverage."

So phase III appears to be a priority. I suppose COVID messed up their plans more than anything else.


So ... a three pronged approach is the way Dan put it ...

1.  Phase 3 for OTENA.
2.  Drug development program - strengthen IP.
3.  Partnering efforts.

And now we know definitively that ATE is focusing on USA, Europe and Japan for partnering (presentation).

I would also bet there are a few surprises possible on the drug development side - even partnering on some development efforts.

I think this is all very smart if you want to go to NASDAQ sooner (2021) rather than later (2022+).
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities